Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 710 participants.
Also called NCT06822790
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 710 participants
- Sponsor
- Registry
-
NCT06822790
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, China, Croatia, Czechia, France, Germany, Hungary, Italy, Japan, Latvia, Lithuania, New Zealand, Poland, Romania, Slovakia, South Africa, Spain, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06822790. Allocation not applicable; no masking; primary purpose treatment. Start 2025-04-09 (actual); primary completion 2028-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- Acronym
- SHASTA-10
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Plozasiran Injection
- Lead sponsor
- Arrowhead Pharmaceuticals
Record details
- Record id
cardio:ct-nct06822790- Content hash
6211ed7023b4b0c477726d36a8ec4b9bf8049a849e4b3e0ff3e9a9e2a6fd815e